Results 131 to 140 of about 77,040 (258)

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives. [PDF]

Drug Deliv
Suo X, Liu Y, Zhang G, Li Y.
europepmc   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Luseogliflozin (TS-071) in Japanese Children and Adolescents With Type 2 Diabetes: A Multicenter, Open-Label, Parallel-Group Phase 1 Study. [PDF]

Clin Pharmacol Drug Dev
Kikuchi T, Nakamura H, Umeuchi H, Kitajima I, Urakami T.   +4 more
europepmc   +1 more source

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Intravenous tobramycin is a first‐line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration‐dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (Cmax) and trough (Cmin) concentrations, the area under the ...
Kiera H. Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee   +6 more
wiley   +1 more source

Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children

British Journal of Clinical Pharmacology, EarlyView.
Codeine is commonly used in combination analgesic products. The use of codeine during breastfeeding can rarely be associated with serious adverse effects related to genetic polymorphisms affecting codeine's metabolism and disposition. Clinicians treating infants of breastfeeding mothers should be aware of this rare but potentially serious complication.
Michael Rieder
wiley   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Implementation of an Integrated Pharmacology Curriculum in a Flipped, Small-Group, Case-Based, Pre-Clerkship Medical Curriculum Improved Student Performance. [PDF]

Pharmacol Res Perspect
Bradaric BD, Van Rite E, Prasad-Reddy L, Bradaric M.   +3 more
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study. [PDF]

Front Immunol
Zhi Y, Zhu R, Sun Y, Lai H, Ren H, Wang Y, Dong L.   +6 more
europepmc   +1 more source